tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Apellis Pharmaceuticals Inc (APLS)
NASDAQ:APLS
US Market
APLS
Apellis Pharmaceuticals
RESEARCH TOOLSreports

Apellis Pharmaceuticals (APLS) Stock News & Sentiment

Compare
991 Followers
Apellis Pharmaceuticals: European Aspaveli Validation and Growing U.S. C3G/IC-MPGN Traction Underpin Buy Rating
Premium
Ratings
Apellis Pharmaceuticals: European Aspaveli Validation and Growing U.S. C3G/IC-MPGN Traction Underpin Buy Rating
1d ago
APLS
Apellis Pharmaceuticals: Syfovre and Empaveli Outperformance Plus Pipeline Upside Support Undervalued Buy Rating and $45 Target
Premium
Ratings
Apellis Pharmaceuticals: Syfovre and Empaveli Outperformance Plus Pipeline Upside Support Undervalued Buy Rating and $45 Target
5d ago
APLS
Apellis Pharmaceuticals: Durable Growth Outlook and Multiple 2025–2026 Catalysts Support Buy Rating
Premium
Ratings
Apellis Pharmaceuticals: Durable Growth Outlook and Multiple 2025–2026 Catalysts Support Buy Rating
5d ago
APLS
Apellis Pharmaceuticals: Empaveli Momentum, Syfovre Franchise Durability, and Multi-Indication Expansion Support Reiterated Buy and $45 Target
Premium
Ratings
Apellis Pharmaceuticals: Empaveli Momentum, Syfovre Franchise Durability, and Multi-Indication Expansion Support Reiterated Buy and $45 Target
5d ago
APLS
Apellis Pharmaceuticals: Buy Rating Affirmed Amidst European Regulatory Milestones and Long-term Growth Potential
Premium
Ratings
Apellis Pharmaceuticals: Buy Rating Affirmed Amidst European Regulatory Milestones and Long-term Growth Potential
1M ago
APLS
Buy Rating for Apellis Pharmaceuticals: Strong Empaveli Launch and Long-term Syfovre Potential
Premium
Ratings
Buy Rating for Apellis Pharmaceuticals: Strong Empaveli Launch and Long-term Syfovre Potential
1M ago
APLS
Promising Potential of Empaveli in Kidney Disease Treatment Drives Buy Rating for Apellis Pharmaceuticals
Premium
Ratings
Promising Potential of Empaveli in Kidney Disease Treatment Drives Buy Rating for Apellis Pharmaceuticals
2M ago
APLS
More APLS News >

APLS News on the Web

Apellis Stock Crashes 23% in a Week: Here's What You Should Know
Zacks
Neutral
Why Apellis Pharmaceuticals, Inc.’s (APLS) Stock Is Down 5.58%
AAII
Neutral
Analysts Conflicted on These Healthcare Names: Apellis Pharmaceuticals (APLS), Sarepta Therapeutics (SRPT) and Mereo Biopharma Group Plc (MREO)
TipRanks News
Neutral
Sobi Announces CHMP's Positive Opinion For Aspaveli
rttnews
Neutral
Why Apellis Pharmaceuticals, Inc.’s (APLS) Stock Is Up 7.57%
AAII
Neutral
Ultragenyx (RARE) Up 14.4% Since Last Earnings Report: Can It Continue?
Zacks
Neutral
Citi Reaffirms Their Buy Rating on Apellis Pharmaceuticals (APLS)
TipRanks News
Neutral
Why Is Halozyme Therapeutics (HALO) Down 2.2% Since Last Earnings Report?
Zacks
Neutral

News Score - Last 7 Days

Neutral
APLS
Sector Average
Media Buzz
This Week3 articles
Weekly Average1 articles
News Sentiment
This Week50%
Sector Average57%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is APLS’s Media Buzz Sentiment?
3 articles about APLS were published this week. In an average week, 1 articles are published.
    What is APLS’s weekly average amount of articles?
    In an average week, 1 articles about APLS are published.
      What is APLS’s News Sentiment?
      50% of articles about APLS were positive this week, compared to its sector average of 57%.
        Healthcare Stocks that are Trending in the News
        CAHCardinal Health
        ALKSAlkermes
        WSTWest Pharmaceutical Services
        AGENAgenus
        PENPenumbra
        Showing the stocks with the most bullish news sentiment over the past week